211 related articles for article (PubMed ID: 15582244)
1. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer.
Klotz L
Eur Urol; 2005 Jan; 47(1):16-21. PubMed ID: 15582244
[TBL] [Abstract][Full Text] [Related]
2. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
Klotz L
Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
[TBL] [Abstract][Full Text] [Related]
3. Active surveillance for prostate cancer: for whom?
Klotz L
J Clin Oncol; 2005 Nov; 23(32):8165-9. PubMed ID: 16278468
[TBL] [Abstract][Full Text] [Related]
4. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease.
Klotz LH
Can J Urol; 2005 Feb; 12 Suppl 1():53-7; discussion 101-2. PubMed ID: 15780167
[TBL] [Abstract][Full Text] [Related]
5. Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer.
Klotz L
Nat Clin Pract Urol; 2005 Mar; 2(3):136-42; quiz 1 p following 149. PubMed ID: 16474710
[TBL] [Abstract][Full Text] [Related]
6. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis.
Klotz LH; Nam RK
Can J Urol; 2006 Feb; 13 Suppl 1():48-55. PubMed ID: 16526983
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
Krakowsky Y; Loblaw A; Klotz L
J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
[TBL] [Abstract][Full Text] [Related]
8. Active surveillance with selective delayed intervention: a biologically nuanced approach to favorable-risk prostate cancer.
Klotz L
Clin Prostate Cancer; 2003 Sep; 2(2):106-10. PubMed ID: 15040871
[TBL] [Abstract][Full Text] [Related]
9. Early outcomes of active surveillance for localized prostate cancer.
Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
[TBL] [Abstract][Full Text] [Related]
10. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
[TBL] [Abstract][Full Text] [Related]
11. Active surveillance for good risk prostate cancer: rationale, method, and results.
Klotz LH
Can J Urol; 2005 Jun; 12 Suppl 2():21-4. PubMed ID: 16018828
[TBL] [Abstract][Full Text] [Related]
12. [Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance].
Leibovici D; Lindner A; Stay K; Zisman A
Harefuah; 2006 Oct; 145(10):763-7, 781, 780. PubMed ID: 17111715
[TBL] [Abstract][Full Text] [Related]
13. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
Efstathiou JA; Chen MH; Catalona WJ; McLeod DG; Carroll PR; Moul JW; Roehl KA; D'Amico AV
Urology; 2006 Aug; 68(2):342-7. PubMed ID: 16904449
[TBL] [Abstract][Full Text] [Related]
15. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.
Klotz L; Zhang L; Lam A; Nam R; Mamedov A; Loblaw A
J Clin Oncol; 2010 Jan; 28(1):126-31. PubMed ID: 19917860
[TBL] [Abstract][Full Text] [Related]
16. Modeling prostate specific antigen kinetics in patients on active surveillance.
Zhang L; Loblaw A; Klotz L
J Urol; 2006 Oct; 176(4 Pt 1):1392-7; discussion 1397-8. PubMed ID: 16952640
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
van den Bergh RC; Roemeling S; Roobol MJ; Wolters T; Schröder FH; Bangma CH
Eur Urol; 2008 Sep; 54(3):505-16. PubMed ID: 18585845
[TBL] [Abstract][Full Text] [Related]
18. Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer.
Klotz L
J Urol; 2004 Nov; 172(5 Pt 2):S48-50; discussion S50-1. PubMed ID: 15535443
[TBL] [Abstract][Full Text] [Related]
19. Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.
van den Bergh RC; Roemeling S; Roobol MJ; Aus G; Hugosson J; Rannikko AS; Tammela TL; Bangma CH; Schröder FH
BJU Int; 2009 Jun; 103(11):1472-7. PubMed ID: 19154509
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]